Our Commitment to a World Without Viral Hepatitis
For decades, we have helped improve the lives of people living with viral hepatitis around the world. We have pioneered cures for hepatitis C (HCV) and have helped transform hepatitis B (HBV) into a manageable condition as we work toward a cure. We have also introduced a therapy for chronic hepatitis D virus (HDV) in Europe.
Now, we have our sights set on achieving the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030. To reach that objective, we're partnering with communities and using a variety of strategies — including disease awareness campaigns and collaboration with governments — to expand access to treatment and providing support for research, testing, diagnosis and other efforts.
Impact
HCV patients cured with Gilead-innovated therapies
Years of commitment to viral hepatitis
Low- and middle-income countries granted low-cost, high-quality medicines
Partnering for an HCV Cure
We developed cures for HCV and collaborate with governments, generic manufacturers and other partners to expand access to our medicines.
We're also going beyond the medicine to help address the disparities impacting people living with hepatitis. Through our corporate giving programs, we partner with community organizations working to ensure people around the world receive care and services.
Advancing Healthier Futures for People Living with HBV
We’ve been advancing the science of HBV for more than two decades. Our research has contributed to today’s scientific understanding of the disease and medical interventions that have transformed how chronic HBV is treated for millions of people around the world.
Now, our focus on advancing innovation drives our research into finding a functional cure.
Addressing Unmet Needs of People Living with HDV
Chronic HDV is the most severe form of viral hepatitis and often underdiagnosed. It can have mortality rates as high as 50% within five years for people with cirrhosis.
Building on our leadership in viral hepatitis, we’re working to bring a first-in-class therapy to regions around the world and to improve access to care for people impacted by HDV.
Gilead’s efforts to strengthen
healthcare systems include:
Gilead has funded hundreds of collaborative studies in hepatitis B, C and D through our External-Sponsored Research programs. Each year we actively contribute to academic and clinical understanding of liver disease, leading to the publications of dozens of scientific manuscripts each year.
We support numerous efforts to expand hepatitis screening and education worldwide, with the goal to identify effective paths to care. For example, through the FOCUS program, we are supporting access to screening and linkage to prevention services for HIV, HCV and HBV.
Our Corporate Giving programs complement our other partnerships by reducing disparities, expanding access and advancing education. For example, through the Gilead All4Liver grant, we have funded more than 80 community-led initiatives across the globe to educate and support people living with HBV, HCV and HDV.
Aiming for a World Without Liver Disease
As we work to meet the demands of an increasingly complex world, we know we can't do it alone. Our partnership mindset helps us strengthen health systems. We proudly partner with communities worldwide to accelerate progress and help ensure broad uptake of treatment for those in need.
HIV
We’re working to end the HIV epidemic — in partnership with the greater HIV community — by pursuing innovations in prevention, treatment and, ultimately, a cure.
Inflammation
We're advancing new treatments to help people living with inflammatory and fibrotic diseases, including primary biliary cholangitis (PBC), inflammatory bowel disease, lupus and metabolic dysfunction-associated steatohepatitis (MASH).